<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and four patients with <z:hpo ids='HP_0011009'>acute</z:hpo> carotid <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> were included in the study </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were divided into 4 groups </plain></SENT>
<SENT sid="2" pm="."><plain>Patients of control group (group 1) were treated with equal basic and reperfusional therapy without any cytoprotectors </plain></SENT>
<SENT sid="3" pm="."><plain>Patients of the 2nd group received citicholine in dose 1000 mg per day </plain></SENT>
<SENT sid="4" pm="."><plain>Patients of the 3rd group were treated with 250 ml actovegin per day </plain></SENT>
<SENT sid="5" pm="."><plain>The NIH <z:hpo ids='HP_0001297'>stroke</z:hpo> scale, the modified Rankin scale and the Barthel index were used to assess neurological status dynamics </plain></SENT>
<SENT sid="6" pm="."><plain>The significant decrease of neurological deficit and improvement of functional recovery were seen in patients treated both with citicholine and actovegin (p &lt; 0.005) to the 30th day compared to the control group </plain></SENT>
<SENT sid="7" pm="."><plain>There was a trend towards the decrease of <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> volume within 5 days after <z:hpo ids='HP_0001297'>stroke</z:hpo> in patients of the 4th group </plain></SENT>
<SENT sid="8" pm="."><plain>No side-effects of citicholine and actovegin were found </plain></SENT>
</text></document>